NASDAQ: TELOTelomir Pharmaceuticals Inc Stock
$2.48-0.01 (-0.4%)
Updated Apr 17, 2025
TELO Price
$2.48
Fair Value Price
$0.04
Market Cap
$73.81M
52 Week Low
$2.38
52 Week High
$8.40
P/E
-4.43x
P/B
114.79x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$16.53M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
1.06
Operating Cash Flow
-$5M
Beta
1.02
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
TELO Overview
Telomir Pharmaceuticals, Inc., a pre-clinical-stage pharmaceutical company, focuses on the development and commercialization of therapeutic treatment for human stem cells. It develops TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic intervention against age-related inflammatory conditions, such as hemochromatosis and osteoarthritis, as well as for post-chemotherapy recovery by interrupting and preventing the interleukin-17 induced inflammatory pathways. The company was formerly known as Metallo Therapies Inc. and changed its name to Telomir Pharmaceuticals, Inc. on October 10, 2022. Telomir Pharmaceuticals, Inc. was incorporated in 2021 and is headquartered in Baltimore, Maryland.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine TELO's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -4.50% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
TELO
Ranked#269 of 463
Ranked#269 of 463
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $2.61 | A | |
| $7.75 | A | |
| $16.85 | A |
Be the first to know about important TELO news, forecast changes, insider trades & much more!
TELO News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how TELO scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
TELO ($2.48) is overvalued by 5,685.91% relative to our estimate of its Fair Value price of $0.04 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
TELO ($2.48) is not significantly undervalued (5,685.91%) relative to our estimate of its Fair Value price of $0.04 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
TELO is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more TELO due diligence checks available for Premium users.
Valuation
TELO fair value
Fair Value of TELO stock based on Discounted Cash Flow (DCF)
Price
$2.48
Fair Value
$0.04
Overvalued by
5,685.91%
TELO ($2.48) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
TELO ($2.48) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
TELO is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
TELO price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-4.43x
Industry
-177.72x
Market
27.98x
TELO price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
114.79x
Industry
4.05x
TELO is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
TELO's financial health
Profit margin
Revenue
$0.0
Net Income
-$2.9M
Profit Margin
0%
TELO's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$1.3M
Liabilities
$681.0k
Debt to equity
1.06
TELO's short-term assets ($1.32M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
TELO's short-term assets ($1.32M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
TELO's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$605.8k
Investing
$0.0
Financing
$1.0M
TELO's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
TELO vs Biotech Stocks
Telomir Pharmaceuticals Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.